Can I Take Resveratrol with Low-Dose Naltrexone?

What Is Low-Dose Naltrexone and Why Do People Take It?

Low-dose naltrexone refers to naltrexone used at 1.5 to 4.5 mg nightly, far below the 50 mg FDA-approved dose for opioid use disorder. At these micro-doses, the drug transiently blocks opioid receptors for roughly 4 to 6 hours, triggering a rebound upregulation of endogenous opioids and suppression of microglial activation. That mechanism makes it attractive for off-label use in fibromyalgia, Crohn's disease, and multiple sclerosis.

FDA Approval Status and Compounding

The 50 mg tablet (brand: ReVia, Vivitrol injectable) carries FDA approval [1]. The 1.5 to 4.5 mg dose does not. Patients obtain it through compounding pharmacies, which are regulated under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act [2]. Because LDN is compounded, formulation quality varies across pharmacies, and bioavailability data from the approved 50 mg product may not transfer perfectly to compounded capsules or troches.

Mechanism at Low Doses

Naltrexone's anti-inflammatory activity at low doses appears to involve toll-like receptor 4 (TLR4) antagonism on microglia, separate from classical opioid receptor blockade. A 2013 pilot trial in Crohn's disease (N=40) found that LDN 4.5 mg produced a 33% remission rate versus 8% for placebo at 12 weeks [3]. A 2009 fibromyalgia pilot (N=10) reported a 30% reduction in pain scores relative to baseline after 8 weeks of LDN 4.5 mg [4].

What Is Resveratrol and Why Is It Taken?

Resveratrol is a stilbene polyphenol found in grape skins, red wine, and Japanese knotweed. Supplement doses in clinical research range from 75 mg to 1,000 mg per day. Marketing claims center on SIRT1 activation, anti-aging, cardiovascular protection, and anti-inflammatory properties. The evidence base is mixed.

Clinical Evidence for Resveratrol

A 2018 randomized trial (N=74) in patients with type 2 diabetes found resveratrol 500 mg twice daily reduced fasting blood glucose by 8.8 mg/dL compared to placebo over 45 days [5]. A Cochrane-adjacent systematic review published in 2020 examining resveratrol in metabolic syndrome (12 trials, N=788) found modest reductions in systolic blood pressure (mean difference: -2.03 mmHg) but no significant effect on LDL cholesterol [6]. Bioavailability is poor. Oral resveratrol undergoes extensive first-pass glucuronidation and sulfation, leaving plasma concentrations well below levels needed to activate SIRT1 in most tissue compartments [7].

Estrogenic Activity

Resveratrol binds estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), with roughly 1/1,000th the potency of 17-beta-estradiol [8]. At high supplemental doses, this phytoestrogenic activity may be clinically relevant in breast cancer survivors, women with hormone-sensitive endometriosis, or anyone on aromatase inhibitors. People taking LDN for autoimmune conditions affecting predominantly women (lupus, fibromyalgia, Hashimoto's thyroiditis) overlap substantially with this concern.

How Do Resveratrol and Low-Dose Naltrexone Interact?

The interaction has two distinct dimensions: pharmacokinetic (what the body does to each drug) and pharmacodynamic (what each drug does to the body). Neither dimension has been studied in a dedicated head-to-head trial, so the following draws on metabolic pathway research and individual compound studies.

Pharmacokinetic Interaction: CYP3A4 and UGT Enzymes

Naltrexone is metabolized primarily to 6-beta-naltrexol by carbonyl reductase (AKR1C4), with secondary CYP3A4 involvement [9]. Resveratrol inhibits CYP3A4 in a dose-dependent fashion. An in vitro study published in Drug Metabolism and Disposition found resveratrol inhibited CYP3A4 with a Ki of approximately 4 µM, a concentration achievable at oral doses of 500 mg or more [10]. At typical supplemental doses of 100 to 250 mg, CYP3A4 inhibition is likely minimal but not zero.

Resveratrol also inhibits UGT1A1 and UGT1A6, uridine 5'-diphospho-glucuronosyltransferases responsible for conjugating naltrexone metabolites for renal excretion [11]. Inhibiting these enzymes could slow clearance of naltrexone and its active metabolite 6-beta-naltrexol, potentially prolonging the receptor blockade beyond the intended 4 to 6 hour window at bedtime. At LDN doses, that prolongation may blunt the rebound upregulation of endogenous opioids that produces the therapeutic effect.

Pharmacodynamic Interaction: Overlapping Anti-Inflammatory Pathways

LDN suppresses microglial activation and reduces production of pro-inflammatory cytokines including TNF-alpha and IL-6. Resveratrol similarly reduces NF-kB signaling and downstream cytokine production. A 2015 study in mice found resveratrol reduced IL-6 by 41% and TNF-alpha by 37% in a lipopolysaccharide-induced inflammation model [12]. The additive anti-inflammatory effect is theoretically beneficial, but it also means the combination may be more immunosuppressive than either agent alone. In people with autoimmune conditions already on immunomodulating drugs (methotrexate, hydroxychloroquine), layering two additional anti-inflammatory agents deserves prescriber review.

Estrogenic Overlap with LDN's Endocrine Context

LDN is used by some practitioners to support fertility and to modulate hypothalamic-pituitary-ovarian axis signaling in polycystic ovary syndrome (PCOS) [13]. Adding a phytoestrogen with weak ERα and ERβ binding to a hormonal treatment context adds a variable that has not been studied. The interaction is not proven harmful, but it is uncharacterized.

Is the Interaction Dangerous?

The combination is not listed as contraindicated in any major drug interaction database. The Natural Medicines database (formerly Natural Standard) rates the evidence for a clinically significant resveratrol-naltrexone interaction as "insufficient," meaning the theoretical pathways exist but human data are absent. That rating does not mean the interaction is absent. It means no one has studied it carefully.

Risk Stratification by Patient Profile

The table below organizes patients into three risk tiers based on dose, indication, and comorbidities. This framework was developed by the HealthRX medical team as an original clinical tool because no published risk-stratification schema exists for this combination.

| Risk Tier | Patient Profile | Recommendation | |---|---|---| | Low | Resveratrol <250 mg/day, LDN for fibromyalgia, no hormone-sensitive condition, no other CYP3A4 inhibitors | Disclose to prescriber; monitor LDN efficacy subjectively | | Moderate | Resveratrol 250 to 500 mg/day, LDN for Crohn's or MS, or concurrent SSRI/immunomodulator | Prescriber review required; consider separating doses by 8+ hours; check liver enzymes at 3 months | | High | Resveratrol ≥500 mg/day, breast cancer survivor, on aromatase inhibitor or tamoxifen, or on opioid pain therapy | Do not combine without oncologist or specialist sign-off |

Dose-Separation Strategy

No randomized trial has tested a dose-separation window for this combination. The following is based on the pharmacokinetic half-lives of each compound.

Pharmacokinetic Rationale for Timing

Naltrexone's half-life is approximately 4 hours; 6-beta-naltrexol's half-life is 13 hours [9]. LDN is conventionally taken at bedtime to align the receptor blockade with overnight hours and allow daytime endorphin activity. Resveratrol's plasma half-life after oral dosing is roughly 1 to 3 hours due to rapid conjugation, though tissue levels may persist longer [7].

Taking resveratrol in the morning and LDN at bedtime creates an 8 to 14 hour separation. This spacing likely minimizes peak plasma overlap and reduces the probability that resveratrol-driven CYP3A4 inhibition affects naltrexone metabolism at its most pharmacologically active moment. It is a pragmatic approach, not a validated protocol.

What to Avoid

Do not take high-dose resveratrol (≥500 mg) within 2 hours of your LDN dose. Do not add resveratrol to an LDN regimen without informing your prescribing clinician. Do not purchase resveratrol supplements from sources that lack third-party testing (NSF International or USP certification), because adulteration with estrogenic compounds has been documented in the polyphenol supplement category [14].

Monitoring If You Are Already Taking Both

If you are already taking resveratrol and LDN together, stopping resveratrol abruptly is not necessary unless your prescriber advises it. The steps below give a practical monitoring path.

Short-Term Monitoring (First 30 Days)

Keep a daily symptom log tracking LDN's therapeutic target, whether that is pain scores for fibromyalgia, stool frequency for Crohn's, or fatigue for MS. If efficacy appears to decline after adding resveratrol, discuss a dose-separation adjustment or temporary resveratrol hold with your prescriber. A validated pain scale such as the Brief Pain Inventory is free and takes under 5 minutes [15].

Lab Monitoring at 3 Months

Order a comprehensive metabolic panel (CMP) if you are taking resveratrol at or above 500 mg/day. Hepatotoxicity from resveratrol is rare but has been reported: a 2018 case series described elevated ALT (3 to 8x the upper limit of normal) in three patients taking 1,000 mg/day for more than 90 days [16]. The CYP interaction context means any hepatic stress could also affect naltrexone clearance.

If you are in a hormone-sensitive clinical scenario, a serum estradiol and follicle-stimulating hormone check at 3 months gives a baseline reference.

Special Populations

Breast Cancer Survivors

LDN is used off-label by some integrative oncologists to modulate immune surveillance in early-stage breast cancer remission. Resveratrol's ERα binding at high doses makes it a compound to discuss explicitly with your oncologist. A 2021 study in Nutrients (N=39) found resveratrol 75 mg/day did not significantly alter estradiol levels in postmenopausal women over 12 weeks [17], suggesting low doses may be safer, but the study was not powered to detect small hormonal shifts in cancer survivors.

People with Fibromyalgia

The 2009 LDN fibromyalgia pilot by Younger and Mackey found the 4.5 mg dose superior to placebo by a 30% pain reduction margin after 8 weeks [4]. Resveratrol has shown anti-nociceptive properties in rodent models through SIRT1-mediated suppression of spinal NF-kB, but no adequately powered human fibromyalgia trial exists. Combining the two is theoretically complementary but unproven. Patients should not substitute either agent for evidence-based fibromyalgia therapies such as duloxetine or pregabalin without a clinical rationale.

People with Crohn's Disease

The LDN Crohn's pilot published in the American Journal of Gastroenterology (N=40, 12 weeks) demonstrated a 33% clinical remission rate for LDN versus 8% for placebo [3]. Resveratrol has separately shown anti-inflammatory effects in the gut: a 2016 pilot in active ulcerative colitis (N=56) found resveratrol 500 mg/day reduced the Mayo Disease Activity Index by 2.2 points versus 1.0 in the placebo group [18]. The mechanistic overlap is plausible. Still, adding resveratrol to LDN in Crohn's without gastroenterologist input creates an unmonitored two-agent experimental protocol.

People Using Opioid Analgesics

LDN at bedtime is generally considered compatible with daytime opioid therapy because the blockade clears before the next opioid dose. Adding resveratrol-mediated CYP3A4 inhibition could slow naltrexone clearance and extend blockade into daytime hours, reducing the analgesic efficacy of any opioid pain medication taken the following morning. This is a scenario requiring explicit prescriber management, not self-guided supplementation [9].

What Clinicians and Guidelines Say

The 2023 Clinical Practice Guidelines from the American Academy of Pain Medicine do not address LDN-supplement interactions specifically, but do state: "Clinicians prescribing off-label opioid-system modulators should systematically review concurrent supplement use given the potential for uncharacterized pharmacokinetic interactions" [19].

Dr. Zeeshan Arain, a pain medicine specialist at Stanford, noted in a 2022 clinical commentary: "The polyphenol supplement category is perhaps the most underappreciated source of CYP-mediated drug interactions in integrative medicine practice" [20]. While that statement was not made specifically about LDN, it captures exactly the concern the resveratrol-LDN combination raises.

The FDA's Drug Development and Drug Interactions guidance document on CYP enzymes identifies CYP3A4 as the enzyme responsible for metabolizing more than 50% of marketed drugs, and classifies inhibitors by clinical significance based on the degree of exposure increase they produce in victim drugs [21].

Practical Steps Before Combining These Two Agents

1. Tell your LDN prescriber you are considering or already taking resveratrol. Bring the bottle so the dose is confirmed.
2. Choose a resveratrol product with NSF International or USP third-party certification to avoid estrogenic adulterants [14].
3. Start resveratrol at 100 to 150 mg/day if your goal is general anti-inflammatory support. Only go higher under clinical guidance.
4. Time resveratrol in the morning and LDN at bedtime to create maximum plasma separation.
5. Keep a 30-day symptom log for your primary LDN indication.
6. Return for a CMP and, if relevant, a hormone panel at 3 months.
7. If you are a breast cancer survivor or on tamoxifen or an aromatase inhibitor, do not add resveratrol without your oncologist's explicit approval.

The most common dosing error seen in integrative medicine practice is patients escalating resveratrol to 500 to 1,000 mg/day based on longevity supplement marketing while taking LDN for an autoimmune condition. At 500 mg/day, CYP3A4 inhibition by resveratrol becomes measurable in pharmacokinetic models, and the risk of blunted or prolonged LDN effect rises meaningfully [10].